New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided

Genentech, a member of the Roche Group, announced new clinical and real-world data for Ocrevus® demonstrating its role in continuing to transform care for people living with relapsing or primary progressive multiple sclerosis presented at the 9th Joint ECTRIMS-ACTRIMS Meeting.